Skip to content

Prospective Assessment in Newborns for Diabetes Autoimmunity

1. Prospective Studies in Infants of the Immunopathogenesis of Type 1 Diabetes 2. Consortium for Identification of Environmental Triggers of Type 1 Diabetes: MCG/UF Clinical Center 3. Identification of Serum Protein Markers for Type 1 Diabetes Using Mass-Spectrometry Techniques 4. Validation of Microarray-Based Biomarkers for Type 1 Diabetes 5. Development of Microarray-Based Biomarkers for Type 1 Diabetes 6. Proteomic Changes/Progression of Human Type 1 Diabetes 7. Identification and Validation of Serum Biomarkers for T1D

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00649246
Acronym
PANDA
Enrollment
25055
Registered
2008-04-01
Start date
1997-07-31
Completion date
2010-08-31
Last updated
2018-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmunity, Type 1 Diabetes

Keywords

genetics, type 1 diabetes, biomarkers, autoimmunity

Brief summary

This is an observational study designed to help researchers understand the genetics and pathogenesis of type 1 diabetes, and to identify biomarkers for disease and disease complication prediction.

Detailed description

This study is designed to identify people who are at risk for developing type 1 diabetes, based on their genetics, family history and autoimmunity status, and to understand the role genetics plays in the development of the complications associated with type 1 diabetes in patients already affected by type 1 diabetes.

Interventions

None listed

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
University of Florida
CollaboratorOTHER
Emory University
CollaboratorOTHER
Medical University of South Carolina
CollaboratorOTHER
University of South Carolina
CollaboratorOTHER
Augusta University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

all are welcome -

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
autoantibodies against the pancreas and type 1 diabetes50 years

Secondary

MeasureTime frame
Risk factors for type 1 diabetes50 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026